Ebenezer Odoom, MD
Geriatric Medicine · Queens Village, NYNPI 1154416691
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,410, 2.3 times the $611 reported in 2019. Among geriatric medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$993
- Novo Nordisk$943
- Pfizer$625
- AstraZeneca$583
- Bayer$446
- Amgen$349
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,351100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $993 |
| Novo Nordisk | 43 | $943 |
| Pfizer | 31 | $625 |
| AstraZeneca | 29 | $583 |
| Bayer | 18 | $446 |
| Amgen(2 entities) | 16 | $349 |
| Mannkind Corporation | 12 | $200 |
| Sanofi-aventis U.S. LLC | 9 | $186 |
| Novartis | 6 | $146 |
| Amarin Pharma, Inc. | 7 | $130 |
| Dexcom, Inc. | 4 | $125 |
| Boehringer Ingelheim | 5 | $115 |
| Merck | 5 | $100 |
| Johnson & Johnson | 4 | $76 |
| ANI Pharmaceuticals, Inc. | 2 | $63 |
| Shield Therapeutics Inc | 3 | $56 |
| Global Blood Therapeutics, Inc. | 2 | $48 |
| Abbott | 2 | $43 |
| Incyte Corporation | 2 | $42 |
| Exact Sciences | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $18 |
How this compares
$5,351 in reported general payments places this provider in the 90th percentile of 400 geriatric medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 38 | $60,472 |
| JardianceEmpagliflozin | 48 | $54,616 |
| EliquisApixaban | 45 | $49,545 |
| OzempicSemaglutide | 38 | $48,557 |
| JanuviaSitagliptin Phosphate | 19 | $25,777 |
| XareltoRivaroxaban | 13 | $21,481 |
| Diclofenac Sodium | 39 | $21,447 |
| EntrestoSacubitril/Valsartan | 22 | $14,420 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $12,710 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $7,005 |
| TradjentaLinagliptin | 12 | $5,900 |
| Novolog FlexpenInsulin Aspart | 20 | $3,835 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $2,822 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 15 | $2,222 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $2,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $115 | $60,51660 claims |
| AstraZenecaFarxiga | $583 | $60,47238 claims |
| PfizerEliquis | $625 | $49,54545 claims |
| Novo NordiskOzempic | $943 | $48,55738 claims |
| MerckJanuvia | $100 | $25,77719 claims |
| Johnson & JohnsonXarelto | $76 | $21,48113 claims |
| NovartisEntresto | $146 | $14,42022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 geriatric medicine providers in New York.
Other geriatric medicine in Queens Village
- Sharad KothariQueens Village$2K
- Wen DombrowskiBrooklyn$45K
- Sharon BrangmanSyracuse$45K
- Howard FillitNew York$42K
- Adam CohenGreat Neck$27K
- Inna ShifrinBrooklyn$21K
- Amit SaxenaBronx$16K
- Nirmala TummalapentaBronx$16K
- Nasem SayeghElmsford$15K
- Bruce LowellGreat Neck$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.